✦ LIBER ✦

The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade : A double blind, randomized, placebo-controlled crossover study

✍ Scribed by Terrence H. Diamond; Julie Winters; Angie Smith; Paul De Souza; John H. Kersley; William J. Lynch; Carl Bryant

Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 96 KB
Volume: 92
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(20010915)92:6<1444::aid-cncr1468>3.0.co;2-m

No coin nor oath required. For personal study only.

✦ Synopsis

BACKGROUND.

Prostate carcinoma therapy with combined androgen blockade may result in high bone-turnover with significant bone loss. This study was undertaken to evaluate the antiosteoporotic efficacy of intravenous pamidronate in a double blind, randomized, placebo-controlled, crossover study.